Eumosone-M

Quick links to important sections

Eumosone-M

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eumosone-M

Quick Facts

Property Description
Active Ingredients Clobetasol Propionate, Miconazole Nitrate
Form Cream, Ointment (Topical preparation)
Pharmacological Class Corticosteroid (Potent), Antifungal Agent (Imidazole)
Origin Synthetic
Type Fixed-Dose Combination (FDC)

Identity and Classification: A Dual-Action Topical Medicine

Eumosone-M is defined as a Fixed-Dose Combination (FDC) topical medicine, a synthetic pharmaceutical product containing two distinct therapeutic agents for direct application to the skin. This FDC is classified into two core pharmacological groups: the Corticosteroids and the Antifungal Agents. The formulation includes Clobetasol Propionate, recognized as a potent glucocorticoid for strong anti-inflammatory action, and Miconazole Nitrate, an azole compound used for its effective fungicidal properties. The Clobetasol Propionate component is classified under the highest potency class of topical corticosteroids.

Composition and Differentiating Factors

Eumosone-M’s composition consists of its two active ingredients: Clobetasol Propionate and Miconazole Nitrate. The medicine is supplied as a semi-solid Topical preparation, typically a Cream or an Ointment. The key differentiating factor of this specific FDC is the inclusion of Clobetasol Propionate, which is designated as very high-potency, setting it apart from combination products that contain milder anti-inflammatory agents. This composition is clinically recognized for addressing conditions characterized by intense inflammation alongside microbial proliferation.

General Purpose and Therapeutic Focus

The general therapeutic purpose of the Eumosone-M formulation is the integrated management of skin disorders where significant inflammation coexists with an active fungal infection. The combination is designed to provide dual action: the potent Clobetasol component focuses on quickly and effectively reducing the symptoms of dermal inflammation, including intense itching and redness, while the Miconazole Nitrate component provides the necessary antifungal action to eliminate the causative organism. This strategy allows the medicine to rapidly address both the patient's symptomatic distress and the underlying microbial pathogen in one step.

What side effects are possible with Eumosone-M?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for Eumosone-M, which contains the corticosteroid clobetasone butyrate and the antifungal miconazole nitrate.

Adverse Reactions

The most commonly reported adverse reactions are local Skin and Subcutaneous Tissue Disorders occurring at the application site. These may include a burning sensation, irritation, itching, skin thinning (atrophy), and redness (erythema). Less common reactions can involve the development of striae (stretch marks), acneiform eruptions, secondary infection, and skin maceration.

Serious Systemic Effects

Due to the presence of a corticosteroid, increased systemic absorption is possible, especially with prolonged use, application to large surface areas, or use under occlusive dressings. This absorption can lead to Endocrine Disorders such as reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome.

Repeated exposure near the eyes must be avoided as it has been associated with the development of cataracts and glaucoma.

Population-Specific Considerations

Pediatric patients are at an increased risk of systemic toxicity and HPA axis suppression due to their higher skin surface area to body weight ratio, which promotes greater absorption. Long-term continuous topical corticosteroid therapy should be avoided in children under 12 years.

Safety Restrictions and Contraindications

Eumosone-M is officially contraindicated and must not be used in the presence of:

  • Untreated primary cutaneous infections (bacterial, viral, fungal, or parasitic).
  • Acne vulgaris or rosacea.
  • Perioral dermatitis.
  • Pruritus (itching) without inflammation.
  • Known hypersensitivity to the active ingredients or any excipient.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the official, regulated information regarding overdose risks associated with Eumosone-M (Clobetasone Butyrate/Miconazole Nitrate combination).

Documented Overdose Risks

Overdose resulting from topical application is primarily linked to the systemic absorption of Clobetasone Butyrate, the corticosteroid component, following prolonged or excessive use over large areas. This can lead to HPA (Hypothalamic-Pituitary-Adrenal) axis suppression and manifestations of hypercortisolism (Cushing's syndrome features).

Overdose Manifestation Exposure Factor
HPA Axis Suppression Prolonged, excessive application
Hypercortisolism Use over large surface areas

Emergency Actions and Vulnerable Populations

In cases where signs of systemic overdose (hypercortisolism) are observed, official regulatory guidance states that the medication should be withdrawn gradually under professional supervision. Infants and children under 12 years are considered a vulnerable population, as they are more susceptible to systemic effects, including adrenal suppression, due to a higher surface area-to-weight ratio. The use of occlusive dressings also increases the risk of systemic absorption and overdose.

Immediate medical help must be sought for accidental ingestion or if any signs of systemic toxicity are apparent.

Therapeutic Uses of Eumosone-M

Eumosone-M is a topical medication generally formulated as a combination treatment for conditions presenting with systemic or localized discomfort that involve both inflammation and a fungal infection. This formulation may assist with managing symptom clusters that may become intense or disruptive, specifically focusing on symptoms related to inflammatory or irritative states and related to physical discomfort.

The medication is commonly used across conditions presenting with acute episodes. The combination is applied across domains where additional symptomatic support is needed. It is relevant in contexts involving heightened systemic burden, such as conditions involving inflammatory or irritative processes that present with episodic or fluctuating manifestations, including steroid-responsive dermatoses.

The combination is commonly used across conditions presenting with acute episodes, such as infected atopic dermatitis, intertrigo, and seborrhoeic dermatitis. The medication supports patients during episodes of heightened discomfort, contributes to easing the overall symptom load, and provides supportive relief when symptoms interfere with routine activities.

“The treatment supports patients during difficult episodes by easing distress.”

Quick Fact: Supportive management for Symptom Clusters

Regulatory References

  1. official product monograph

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Eumosone-M (Clobetasone Butyrate and Miconazole Nitrate) eligibility is strictly defined by regulatory labeling, which outlines groups who must not use the medicine and populations requiring special caution.

Classification Regulatory Status
Contraindicated Individuals with known hypersensitivity to any component.
Excluded Conditions Must NOT be used on areas with untreated primary bacterial or viral infections, rosacea, acne vulgaris, or pruritus (itching) without inflammation.

Special Population Caution:

  • Age-Related: Use in children under 12 years is generally not recommended and, if prescribed, should be for the shortest duration and minimum quantity due to the increased risk of systemic absorption of the steroid component.
  • Pregnancy/Lactation: Use is generally not recommended unless the potential benefit justifies the risk, as safety data is limited. If used while breastfeeding, application to the breast area must be avoided.
  • Organ Function: Patients with severe hepatic or renal impairment may have delayed drug elimination if systemic absorption occurs, necessitating caution and minimal use.

Only a healthcare provider can determine if this medicine is appropriate based on the official eligibility profile and individual clinical need.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Eumosone-M outlines specific interaction patterns, primarily related to the systemic effects of its active ingredients despite being a topical product. The overall profile is defined by pharmacokinetic interactions that may modify the concentration of co-administered systemic medicines.


Drug-Drug Interaction Profile

Oral Anticoagulants

The most critical documented interaction involves co-administration with oral anticoagulants, such as Warfarin. Regulatory guidance highlights that the Miconazole Nitrate component is known to inhibit the metabolic enzymes CYP2C9 and CYP3A4. This enzyme inhibition can lead to an increased anticoagulant effect due to reduced clearance of the blood thinner. Official prescribing information for this use-with-caution combination mandates that the anticoagulant effect must be carefully monitored in patients receiving concurrent therapy.

Strong Metabolic Inhibitors

Co-administration with strong systemic CYP3A4 inhibitors, including medicines like Ritonavir or Itraconazole, may inhibit the metabolism of the Clobetasol Propionate component. This pharmacokinetic interaction is formally noted in regulatory labeling as resulting in increased systemic exposure to the corticosteroid, depending on the dosage and route of the inhibitor.

Food and Other Substances

No specific timing separation rules or restrictions concerning interactions with common substances such as food, alcohol, or herbal products are explicitly documented in the official regulatory information for this topical combination.

Mechanism of Action

Glucocorticoid Receptor-Mediated Pathway Suppression

The corticosteroid component, Clobetasol Propionate, acts as an agonist for the Glucocorticoid Receptor (GR), initiating a cascade that involves genomic modulation. This mechanism upregulates anti-inflammatory proteins, such as Annexin A1, which blocks the upstream release of Arachidonic Acid. By suppressing this key step, the synthesis of potent inflammatory mediators like prostaglandins and leukotrienes is reduced, resulting in the suppression of local vascular and cellular responses within the dermis.

Targeted Disruption of Fungal Membrane Synthesis

The antifungal component, Miconazole Nitrate, operates by inhibiting the essential fungal enzyme 14alpha-demethylase. This blocks the conversion of lanosterol into Ergosterol, a crucial structural sterol for the fungal cell membrane. The resulting depletion of Ergosterol and accumulation of toxic sterols severely compromises the membrane's integrity, leading to cellular failure and a fungicidal outcome that eliminates the source of the microbial irritation.

Complementary Mechanistic Synergy

The mechanism integrates two pharmacodynamic actions: the modulation of host responses and the disruption of pathogen structure. Clobetasol induces rapid suppression of local physiological responses (inflammation suppression and local vasoconstriction), while Miconazole provides the definitive pathogen eradication. This concurrent action supports a combined physiological effect resulting from the dual mechanisms acting simultaneously.

Dosage and Administration Information

How to Use Eumosone-M: Official Administration Guidelines

This section describes the official, label-based usage principles for Eumosone-M, a topical combination of Clobetasol Propionate and Miconazole Nitrate.


Administration Scope

Instruction Detail
Route of administration: Topical application only, directly onto the skin. The medicine is strictly for external use.
Dosing schedule: A thin layer is applied to the affected areas. The total quantity applied should not exceed 50 grams per week for the Clobetasol Propionate component.
Frequency and duration: Application is typically twice daily (BID), in the morning and evening, rubbed in gently and completely. Treatment is generally limited to 2 consecutive weeks to mitigate the risk of systemic absorption.
Age-group rules: Use in children under 12 years of age is not recommended due to the potent nature of the corticosteroid component.
Course completion: Therapy should be discontinued promptly when control has been achieved, even if the maximum duration limit of two weeks has not been reached.

Special Procedural Conditions

Constraint Requirement
Occlusion: The treated area must not be bandaged, covered, or wrapped with occlusive dressings unless explicitly instructed by a healthcare provider.
Restricted Areas: Application must be avoided on highly sensitive areas, including the face, groin, and axillae (underarms).

These official instructions establish a precise, time-limited topical administration protocol. This protocol mandates a twice-daily frequency for a short duration and explicitly constrains application methods and areas to minimize potential systemic uptake, formalizing the standardized approach required for this formulation.

Recent Clinical Evidence

Eumosone-M: Recent Clinical Evidence

Eumosone-M is a topical combination containing clobetasone butyrate (a moderate-strength corticosteroid) and miconazole nitrate (an imidazole antifungal agent). Clinical research focuses on evaluating its combined effect in treating skin conditions that involve both inflammation and fungal infection.


Efficacy Data: Outcomes in Controlled Trials

Studies evaluating the individual components and combinations like Eumosone-M primarily use controlled trials to assess patient-reported outcomes such as changes in symptoms. Research has monitored the following:

  • Symptom Resolution: Clinical trials examine whether the combination leads to a reduction in inflammation, redness, and pruritus (itching) associated with fungal skin infections (e.g., ringworm, jock itch, and athlete's foot).
  • Antifungal Action: Miconazole is studied for its ability to inhibit the growth and spread of common fungi like Candida species and dermatophytes, a necessary component for overall mycological clearance.
  • Corticosteroid Effect: Clobetasone butyrate is included in the formulation to manage the inflammatory response that often accompanies the infection, with studies observing its effect on reducing swelling and irritation.

Safety and Tolerability Profile

Topical safety data for the combination focuses on local adverse reactions. Commonly reported events in clinical settings and post-marketing surveillance include application site reactions such as temporary burning sensation, irritation, itching, and redness. The use of topical corticosteroids requires specific consideration, particularly concerning the risk of localized skin thinning or systemic absorption, especially in children or when applied to large surface areas or the face. Regulatory warnings emphasize that the product should not be used for untreated primary bacterial or viral infections, acne vulgaris, or rosacea.

Frequently Asked Questions (FAQ)

Common questions about Eumosone-M (FAQ)


Q: Does Eumosone-M help with redness and inflammation?

A: Official product information indicates that Eumosone-M is used for the relief of inflammatory and pruritic (itchy) manifestations of responsive skin conditions. The corticosteroid component is specifically included in the formulation to help reduce symptoms like redness, swelling, and irritation on the skin.


Q: Is Eumosone-M stronger than regular Eumosone cream?

A: Eumosone-M is a Fixed-Dose Combination product. While it contains the same corticosteroid as Eumosone, the 'M' signifies the addition of an antifungal agent. The addition of the antifungal agent means the product is formulated to address both the inflammation and a suspected or present fungal infection simultaneously.


Q: Is it normal to feel a slight burning sensation when applying Eumosone-M?

A: Regulatory safety information indicates that local adverse reactions, such as a temporary burning sensation, irritation, or itching, are among the commonly reported effects at the application site. These types of reactions should be monitored and mentioned to a healthcare provider.


Q: Are there any long-term side effects from using Eumosone-M on a small area?

A: Official warnings state that prolonged or continuous use is discouraged due to the increased risk of local side effects. This includes effects like skin thinning (atrophy). Regulatory guidelines emphasize that use should be limited to the shortest possible duration.


Q: Why do doctors prescribe Eumosone-M instead of a simpler cream?

A: Official labeling states that Eumosone-M is indicated for conditions where both inflammation and itching coexist with a secondary fungal infection, or where such an infection is suspected. It is designed to deliver both potent anti-inflammatory relief and antifungal treatment in one step.


Q: Can Eumosone-M be used for psoriasis or just eczema?

A: Regulatory documents indicate that this medicine is used to treat a range of steroid-responsive dermatoses where fungal infection is present or suspected. This commonly includes conditions such as atopic dermatitis (eczema) and seborrhoeic dermatitis.


Q: What are the inactive ingredients in Eumosone-M?

A: The full product information lists all inactive ingredients, also known as excipients. These can include various components of the cream base and preservatives, such as chlorocresol. The complete list is provided within the detailed regulatory product information.


Q: Will Eumosone-M still work if I keep it in the refrigerator?

A: Official storage instructions advise keeping the product in a cool, dry place at the recommended room temperature, typically ranging from 10 C to 25 C. The stability of the product requires protection from freezing or excessive heat, and it should be stored within the temperature range specified on the packaging.


Q: Does Eumosone-M contain parabens or lanolin?

A: The entire list of all ingredients, including potential excipients such as parabens or lanolin, is specified in the full regulatory composition section. The presence of these specific ingredients can be verified by reviewing the detailed regulatory product composition.


Q: Can I apply makeup or moisturizer over Eumosone-M?

A: Official guidance advises allowing adequate time for the cream to be absorbed into the skin before applying an emollient (moisturizer). There is no specific regulatory instruction regarding the application of makeup.


Q: Why is Eumosone-M sometimes prescribed for conditions that don't look infected?

A: The combination may be prescribed even when an infection is not clearly visible because it is indicated for cases where a fungal infection is suspected or considered likely to occur. This allows the antifungal agent to be used alongside the steroid's potent anti-inflammatory action.


Q: Can Eumosone-M cause changes in skin pigmentation?

A: Regulatory documents indicate that changes in the skin's color or pigmentation (such as lightening or darkening) have been reported as a less common side effect associated with the use of topical corticosteroids.


Q: Can Eumosone-M be used on the scalp for scalp dermatitis?

A: The product is for topical application to the skin to manage conditions like seborrhoeic dermatitis. However, specific product information should be checked, as the efficacy of cream formulations on dense, hair-bearing areas like the scalp may be limited.


Q: What is the perceived benefit of a combination cream like Eumosone-M?

A: The key benefit, as outlined in official indications, is the integrated approach to skin disorders. It combines the rapid anti-inflammatory action of the steroid with the necessary antifungal action to address the root cause and the symptoms simultaneously in one step.


Q: Is Eumosone-M safe for use by elderly patients (general concern)?

A: Official labels for the corticosteroid component note that use in the elderly population is considered for steroid-responsive dermatoses. As with all patient groups, caution is warranted to minimize the risk of increased systemic absorption, particularly with prolonged use.


Q: Are there any common foods or drinks that interact with Eumosone-M?

A: Regulatory information for this topical combination does not list any specific restrictions or required timing separation rules concerning interactions with common substances such as food, alcohol, or herbal products.


Q: What research supports the use of Eumosone-M for mixed skin conditions?

A: The formulation is supported by the established pharmacodynamic properties of both active ingredients. Regulatory documents detail the combined mechanism of action, which includes the anti-inflammatory effects of the steroid and the antifungal effects of miconazole, both demonstrated in pre-clinical and clinical testing.

How should Eumosone-M be stored and disposed of?

How to Store and Dispose of Eumosone-M?

This medicine must be stored according to regulatory requirements to maintain its stability.


Storage & Disposal Scope

Requirement Official Regulatory Statement
Labeled storage temperature requirements Store in a cool and dry place; typically 10 C to 25 C or below 30 C.
Light/moisture protection requirements Must be protected from moisture, sunlight, and heat.
Packaging-related storage rules Store in its original container and do not use after the expiry date.
Child-protection storage requirements Keep out of the reach and sight of children.
Disposal instructions (as documented in government sources) Dispose of the unused medicine according to local regulations.

Resulting Storage & Disposal Structure

Official storage and disposal statements:

  • Store the cream in a cool, dry place, protecting it from freezing or excessive heat.
  • The product must remain in its original container and should never be used past its labeled expiry date.
  • Keep Eumosone-M out of the sight and reach of children to prevent accidental exposure.

Connection to the overall storage/disposal profile (2–4 sentences): Regulatory documents define storage by mandating specific temperature and environmental constraints to protect the product's integrity. The disposal protocol requires that unused or expired medicine be discarded in accordance with local pharmaceutical regulations, preventing entry into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eumosone-M found in:

A-Z Index: